Coronavirus Update: Trial Of Lilly's Antibody Is Next To Be Paused
Plus: Hyperimmune Globulin Trial Launched
• By Scrip Team
The ACTIV-3 Trial is being conducted by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).
Keep up with the top pharma business news of the week. On the go.
